ATG16L1 and prostate cancer: We have also presented additional evidence for a role of ATG16L1 in prostate cancer, as downregulated ATG16L1 gene expression in tumors was correlated with poorer clinical outcomes, and thereby strengthening the evidence of this genotype-phenotype association.